Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Mi Ran Yun(Yonsei University), Byoung Chul Cho(Yonsei University)

EMBO Molecular Medicine

October 21, 2019

10.15252/emmm.201910581

Cited by 60

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.3k

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

|Nature Medicine|2015|1.5k

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

|New England Journal of Medicine|2020|835

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

|The Lancet Oncology|2019|537

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

|The Lancet Oncology|2020|413